| Date Filed | Type | Description |
| 03/22/2021 |
GN
| Opiant Pharmaceuticals Strengthens Board of Directors With Appointment of Seasoned Clinical Development Executive Lorianne Masuoka, M.D. |
| 02/08/2021 |
GN
| Opiant Pharmaceuticals Announces First Patient Dosed in Confirmatory Pharmacokinetic Study Assessing OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose |
| 12/14/2020 |
GN
| Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program |
| 12/10/2020 |
GN
| Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing |
| 12/07/2020 |
GN
| Opiant Pharmaceuticals Announces Appointment of Biopharmaceutical Leader Craig A. Collard as Chairman to its Board of Directors |
| 08/31/2020 |
GN
| Opiant Pharmaceuticals to Participate at the 2020 Cantor Global Virtual Healthcare Conference |
| 08/06/2020 |
GN
| Opiant Pharmaceuticals Announces Second Quarter 2020 Financial Results and Corporate Update |
| 06/05/2020 |
GN
| Opiant Pharmaceuticals Statement on U.S. District Court Decision |
| 05/26/2020 |
GN
| Opiant Pharmaceuticals to Present at the 2020 Jefferies Virtual Healthcare Conference |
| 05/21/2020 |
GN
| Opiant Pharmaceuticals to Hold Virtual 2020 Annual Shareholder Meeting |
| 05/12/2020 |
GN
| Opiant Pharmaceuticals Announces First Quarter 2020 Financial Results and Corporate Update |
| 04/28/2020 |
GN
| Opiant Pharmaceuticals to Report First Quarter 2020 Financial Results and Host Conference Call and Webcast on Tuesday, May 12 |
| 03/04/2020 |
GN
| Opiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update |
| 01/02/2020 |
GN
| Opiant Pharmaceuticals Announces Development Collaboration with National Center for Advancing Translational Sciences for the Development of OPNT004 for the Treatment of Acute Cannabinoid Overdose |
| 12/12/2019 |
GN
| Opiant Pharmaceuticals Announces Contract Extension of Second Tranche of Approximately $2.4 Million from Biomedical Advanced Research and Development Authority for Development of OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose |
| 11/12/2019 |
GN
| Opiant Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update |
| 09/24/2019 |
GN
| Opiant Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference |
| 08/27/2019 |
GN
| Opiant Pharmaceuticals Announces Presentations at Two Upcoming Investor Conferences |
| 04/08/2019 |
GN
| Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT003, Nasal Nalmefene, for Treatment of Synthetic Opioid Overdose |
| 04/03/2019 |
GN
| Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT002, Nasal Naltrexone, for Treatment of Alcohol Use Disorder |
| 04/01/2019 |
GN
| Opiant Pharmaceuticals Announces Award of Second Tranche of Approximately $3.0 Million from National Institutes of Health Grant for Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose |
| 03/21/2019 |
GN
| Opiant Pharmaceuticals, Inc. Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update |
| 12/26/2018 |
GN
| Opiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi |
| 12/24/2018 |
GN
| Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent |
| 11/19/2018 |
GN
| New Research: Key Drivers of Growth for Huttig Building Products, Stratus Properties, Manitex International, Marathon Patent Group, Medallion Financial, and Opiant Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production |
| 11/05/2018 |
GN
| Opiant Pharmaceuticals Announces Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa |
| 10/29/2018 |
GN
| Opiant Pharmaceuticals Appoints Seasoned Pharmaceutical Executive Craig Collard to Board of Directors |
| 09/26/2018 |
GN
| Opiant Pharmaceuticals to Present at the Cantor Global Healthcare Conference |
| 09/25/2018 |
GN
| Opiant Pharmaceuticals Announces Pricing of Public Offering of Common Stock |
| 09/24/2018 |
GN
| Opiant Pharmaceuticals Announces Proposed Public Offering of Common Stock |
| 09/10/2018 |
GN
| Opiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose |
| 08/16/2018 |
GN
| Investor Expectations to Drive Momentum within Capital Senior Living, Thermon Group, L.B. Foster, Anavex Life Sciences, Opiant Pharmaceuticals, and Huron Consulting Group — Discovering Underlying Factors of Influence |
| 08/09/2018 |
GN
| Opiant Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results and Provides Corporate Update |
| 06/25/2018 |
GN
| Opiant Pharmaceuticals Announces Receipt of First Tranche from National Institutes of Health Grant for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose |
|